Epidemiology of IFIs: an update

J.V. Guinea Ortega

Author address: 

Madrid, ES)

Abstract: 

The growing number of immunocompromised patients could account for the increased number of invasive fungal infections (IFIs) detected. However, the use of corticosteroids, intravascular devices, and other aggressive procedures may also be responsible for the increase in the number and different types of patients at risk of developing IFIs. An accurate study of the epidemiology of IFIs requires reliable diagnostic tools, yet our knowledge of epidemiology in IFIs is limited by the difficulty in establishing a diagnosis. Invasive candidiasis is the most common IFI and is particularly prevalent in patients carrying intravascular catheters, those undergoing abdominal surgery, and very-low-birth-weight newborns. Although Candida albicans is still the main etiologic agent in invasive candidiasis, other non-albicans Candida species are becoming increasingly prevalent. Knowledge of local epidemiology is important, as susceptibility to antifungal agents is mainly based on the species involved, which vary with geography. Furthermore, widespread use of antifungal agents is also contributing to antifungal resistance. Invasive aspergillosis and other mold infections have classically affected patients with hematological cancer in periods of deep and prolonged neutropenia and recipients of solid organ or bone marrow transplant. Today, the population at risk of acquiring mold infections is more heterogeneous and includes patients with chronic lung diseases receiving long-term corticosteroid therapy. Environmental factors may also contribute to invasive aspergillosis in patients with a relatively sound immune status, such as those undergoing major surgery. Invasive aspergillosis is caused mainly by Aspergillus fumigatus; however, recent advances in fungal taxonomy have uncovered a more complex
2012

abstract No: 

NULL

Full conference title: 

22nd European Congress of Clinical Microbiology and Infectious Diseases
    • ECCMID 22nd (2012)